Compare AKR & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKR | LIVN |
|---|---|---|
| Founded | 1993 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.5B |
| IPO Year | 1996 | 2015 |
| Metric | AKR | LIVN |
|---|---|---|
| Price | $21.29 | $79.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $22.25 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 1.3M | 647.9K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.27 | ★ 2.33 |
| Revenue | ★ $410,757,000.00 | N/A |
| Revenue This Year | $3.21 | $9.79 |
| Revenue Next Year | $12.17 | $6.63 |
| P/E Ratio | $79.04 | ★ $33.59 |
| Revenue Growth | ★ 14.20 | N/A |
| 52 Week Low | $18.61 | $48.82 |
| 52 Week High | $23.03 | $85.76 |
| Indicator | AKR | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 51.24 | 46.07 |
| Support Level | $20.87 | $74.99 |
| Resistance Level | $21.41 | $81.83 |
| Average True Range (ATR) | 0.46 | 2.24 |
| MACD | 0.05 | -0.23 |
| Stochastic Oscillator | 47.63 | 45.95 |
Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company operates through three segments: REIT Portfolio segment consists of high-quality retail properties located in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon; Investment Management segment holds the retail real estate in which the company co-invests with high-quality institutional investors; and Structured Financing segment consists of earnings and expenses related to notes and mortgages receivable Fees earned by the company as the general partner or managing member through Investment Management.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.